The Magazine for Sleep Professionals
Saturday, August 29, 2026
Takeda announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved the use of ORZEYFUL (oveporexton) for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. ORZEYFUL is a first-in-class oral orexin receptor 2 (OX2R) agonist and the only medicine indicated in Japan to treat […]
Takeda announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. […]
The U.S. Food and Drug Administration today approved Orzeyful (oveporexton) tablets for the treatment of narcolepsy type 1 in adults. Orzeyful is the first medicine approved for narcolepsy type 1 as a complete disorder — addressing the full range of symptoms that define the condition — and the first to […]
Lundbeck announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Lu AH69593, the company’s lead oral orexin 2 receptor agonist and one of several investigational compounds in Lundbeck’s development portfolio for sleep-wake disorders. Lu AH69593 was discovered by Lundbeck and it is presently in […]
Takeda China announced that the National Medical Products Administration of China has approved the use of ORZEYFUL (oveporexton) for the treatment of narcolepsy type 1 (NT1) in adolescents aged 16 years and older and adults. Oveporexton is the first oral orexin receptor 2 (OX2R)-selective agonist approved in China and is the […]
There I was—in class again. Tired again. Such is the life of a graduate student. When you’re going to class, working, and completing an internship, “tired” is the norm. As I woke up from one of my many naps that day, I saw that today’s class was on sleep disorders, […]
New data presented by Takeda at SLEEP 2026 this week continues to build the case for oveporexton (TAK-861) as a potential disease-modifying treatment for narcolepsy type 1 (NT1). Oveporexton is designed to address the root cause of the disease, targeting the underlying orexin deficiency responsible for NT1. Results from two pivotal […]
Alkermes plc announced plans to present new data from its industry-leading portfolio of sleep medicine research at SLEEP 2026, the 40th annual meeting of the Associated Professional Sleep Societies (APSS), taking place June 14-17, 2026 in Baltimore, MD. The company will present 26 abstracts, including posters featuring LUMRYZ® (sodium oxybate) extended-release oral […]
Jazz Pharmaceuticals announced that the company will present 21 abstracts, including 11 late-breaking abstracts, at SLEEP 2026, the 40th annual meeting of the Associated Professional Sleep Societies (APSS), taking place June 14-17, 2026, in Baltimore. The robust breadth of data reflects Jazz’s continued focus on advancing treatment for rare and difficult-to-treat sleep […]
Narcolepsy Network, a national non-profit organization for people living with narcolepsy and idiopathic hypersomnia (IH), is pleased to announce the appointment of Liz Burgess as its new Executive Director. Liz has dedicated her career to mission-driven leadership, serving for more than 20 years as an Executive Director of a diverse range of nonprofit […]
